GLP-1 category in the research catalog
The GLP-1 category in our product catalog covers receptor agonist analogs used in metabolic pathway and in-vitro signaling research. NeoBio lists Semaglutide 5mg and Tirzepatide 10mg alongside other research categories such as Healing & Recovery, Growth & Secretagogue, and Copper Peptide.
Home page category copy describes GLP-1 materials as receptor agonist analogs for metabolic pathway research—a framing consistent with laboratory R&D use, not clinical application.
Semaglutide 5mg — GLP-1 receptor agonist analog
Semaglutide 5mg is listed as a GLP-1 receptor agonist analog for metabolic pathway research. The catalog notes lyophilized supply with independent lab verification on published lots.
Availability varies by manufacturing cycle; check the product catalog for current stock status. Custom synthesis inquiries for qualified research accounts are accepted via the contact page.
Tirzepatide 10mg — dual GIP/GLP-1 receptor agonist
Tirzepatide 10mg is described as a dual GIP/GLP-1 receptor agonist for advanced in-vitro metabolic research programs. Published COA records include lot AR-TIRZ-2501A with 99.0% HPLC purity from January 2025 third-party testing.
Researchers should match vial lot numbers to certificates on the Lab Testing / COAs page before initiating receptor binding or stability work.
Quality assurance and compliance reminders
All catalog peptides are for laboratory research and development only. Purchasers must be 21 years or older. Products are not intended to diagnose, treat, cure, or prevent any disease.
NeoBio combines rigorous third-party testing with published COAs and clear RUO labeling—supporting institutional buyers who need documentation aligned with compliance expectations.